The efficacy and safety of drug-eluting balloons for the treatment of in-stent restenosis as compared with drug-eluting stents and with conventional balloon angioplasty
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Treatment of coronary in-stent restenosis (ISR) is still associated with a high incidence of recurrence. We aimed to compare the efficacy and safety of drug-eluting balloons (DEB) for the treatment of ISR as compared with conventional balloon angioplasty (BA) and drug-eluting stents (DES). Methods: Between January 2006 and May 2012 a total of 177 patients (188 lesions, 64.1 ± 11.7 years old) who underwent percutaneous coronary intervention for ISR were retrospectively enrolled. Clinical outcomes were compared between patients treated with DEB (n = 58, 32.8%), conventional BA (n = 65, 36.7%), or DES (n = 54, 30.5%). The primary end point was a major adverse cardiac event (MACE), defined as a composite of cardiac death, myocardial infarction, and target lesion revascularization (TLR). Results: Baseline characteristics were not different except for a history of previous MI, which was more frequent in patients treated by conventional BA or DES than in patients treated by DEB (40.0% vs. 48.1% vs. 17.2%, respectively, p = 0.002). The total incidences of MACEs were 10.7%, 7.4%, and 15.4% in patients treated by DEB, DES, or conventional BA, respectively (p > 0.05). TLR was more frequent in patients treated by conventional BA than in patients treated by DEB or DES, but this was not statistically significant (10.8% vs. 6.9% vs. 3.7%, p > 0.05 between all group pairs, respectively). Conclusions: This study showed that percutaneous coronary intervention using DEB might be a feasible alternative to conventional BA or DES implantation for treatment of coronary ISR. Further large-scaled, randomized study assessing long-term clinical and angiographic outcomes will be needed.
Abstract
Background/Aims: Treatment of coronary in-stent restenosis (ISR) is still associated with a high incidence of recurrence. We aimed to compare the efficacy and safety of drug-eluting balloons (DEB) for the treatment of ISR as compared with conventional balloon angioplasty (BA) and drug-eluting stents (DES). Methods: Between January 2006 and May 2012 a total of 177 patients (188 lesions, 64.1 ± 11.7 years old) who underwent percutaneous coronary intervention for ISR were retrospectively enrolled. Clinical outcomes were compared between patients treated with DEB (n = 58, 32.8%), conventional BA (n = 65, 36.7%), or DES (n = 54, 30.5%). The primary end point was a major adverse cardiac event (MACE), defined as a composite of cardiac death, myocardial infarction, and target lesion revascularization (TLR). Results: Baseline characteristics were not different except for a history of previous MI, which was more frequent in patients treated by conventional BA or DES than in patients treated by DEB (40.0% vs. 48.1% vs. 17.2%, respectively, p = 0.002). The total incidences of MACEs were 10.7%, 7.4%, and 15.4% in patients treated by DEB, DES, or conventional BA, respectively (p > 0.05). TLR was more frequent in patients treated by conventional BA than in patients treated by DEB or DES, but this was not statistically significant (10.8% vs. 6.9% vs. 3.7%, p > 0.05 between all group pairs, respectively). Conclusions: This study showed that percutaneous coronary intervention using DEB might be a feasible alternative to conventional BA or DES implantation for treatment of coronary ISR. Further large-scaled, randomized study assessing long-term clinical and angiographic outcomes will be needed.
참고문헌 (19)
- Stettler C, "Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis", Lancet, 370, pp.937~948 (2007)
- Wohrle J, "Comparison of the slow-release polymer-based paclitaxel-eluting Taxus-Express stent with the bare-metal Express stent for saphenous vein graft interventions", Clin Res Cardiol, 96, pp.70~76 (2007)
- Dangas GD, "In-stent restenosis in the drug-eluting stent era", J Am Coll Cardiol, 56, pp.1897~1907 (2010)
- Scheller B, "Drug-coated balloons: the new gold standard for treatment of coronary in-stent restenosis?", Cardiovasc Revasc Med, 13, pp.257~259 (2012)
- Scheller B, "Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter", N Engl J Med, 355, pp.2113~2124 (2006)
- Habara S, "Effectiveness of paclitaxel-eluting balloon catheter in patients with sirolimus-eluting stent restenosis", JACC Cardiovasc Interv, 4, pp.149~154 (2011)
- Scheller B, "Long-term follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter", JACC Cardiovasc Interv, 5, pp.323~330 (2012)
- Rittger H, "A randomized, multicenter, single-blinded trial comparing pa-clitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study", J Am Coll Cardiol, 59, pp.1377~1382 (2012)
- Mauri L, "Stent thrombosis in randomized clinical trials of drug-eluting stents", N Engl J Med, 356, pp.1020~1029 (2007)
- Mehran R, "Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome", Circulation, 100, pp.1872~1878 (1999)
- Alfonso F, "A randomized comparison of repeat stenting with balloon angioplasty in patients with in-stent restenosis", J Am Coll Cardiol, 42, pp.796~805 (2003)
- Kastrati A, "Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial", JAMA, 293, pp.165~171 (2005)
- Iofina E, "Sirolimus-and paclitaxel-eluting stents in comparison with balloon angioplasty for treatment of in-stent restenosis", Catheter Cardiovasc Interv, 64, pp.28~34 (2005)
- Radke PW, "Treatment of in-stent restenosis using a paclitaxel-eluting stent: acute results and long-term follow-up of a matched-pair comparison with intracoronary beta-radiation therapy", Eur Heart J, 25, pp.920~925 (2004)
- Indermuehle A, "Drug-eluting balloon angioplasty for in-stent restenosis: a systematic review and meta-analysis of randomised controlled trials", Heart, 99, pp.327~333 (2013)
- Waksman R, "Drug-eluting balloon: the comeback kid?", Circ Cardiovasc Interv, 2, pp.352~358 (2009)
- Scheller B, "Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter", Clin Res Cardiol, 97, pp.773~781 (2008)
- Unverdorben M, "Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis", Circulation, 119, pp.2986~2994 (2009)
- Byrne RA, "Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial", Lancet, 381, pp.461~467 (2013)